Stock 301201 CHENGDA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ChengDa Pharmaceuticals Co., Ltd.

Equities

301201

CNE100005766

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
22.68 CNY +3.00% Intraday chart for ChengDa Pharmaceuticals Co., Ltd. +12.22% -10.81%
04-21 ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-01 Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024. CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 4,912 3,934
Enterprise Value (EV) 1 3,531 2,570
P/E ratio 45.2 x 43.2 x
Yield 0.59% -
Capitalization / Revenue 11.9 x 9.5 x
EV / Revenue 8.58 x 6.2 x
EV / EBITDA 33.5 x 25.4 x
EV / FCF -18.4 x -56.3 x
FCF Yield -5.43% -1.78%
Price to Book 2.22 x 1.73 x
Nbr of stocks (in thousands) 154,714 154,714
Reference price 2 31.75 25.43
Announcement Date 23-04-23 24-04-21
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 373 415.7 411.5 414.3
EBITDA 1 128.3 142.6 105.5 101.2
EBIT 1 101.9 112.1 70.27 60.62
Operating Margin 27.32% 26.96% 17.08% 14.63%
Earnings before Tax (EBT) 1 139.5 115.3 120.1 104.2
Net income 1 121.2 100.4 106.5 90.98
Net margin 32.48% 24.16% 25.88% 21.96%
EPS 2 1.044 0.8656 0.7029 0.5881
Free Cash Flow 1 57.1 -98.29 -191.8 -45.63
FCF margin 15.31% -23.64% -46.61% -11.01%
FCF Conversion (EBITDA) 44.52% - - -
FCF Conversion (Net income) 47.12% - - -
Dividend per Share - 0.4500 0.1875 -
Announcement Date 22-04-18 22-04-18 23-04-23 24-04-21
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - 50.6 - -
Net Cash position 1 37 - 1,381 1,364
Leverage (Debt/EBITDA) - 0.3547 x - -
Free Cash Flow 1 57.1 -98.3 -192 -45.6
ROE (net income / shareholders' equity) 29.3% 20.3% 7.76% 4.05%
ROA (Net income/ Total Assets) 11.8% 11.5% 2.92% 1.59%
Assets 1 1,028 872.8 3,643 5,736
Book Value Per Share 2 3.950 4.560 14.30 14.70
Cash Flow per Share 2 0.4100 0.1600 3.910 8.820
Capex 1 63.8 139 206 225
Capex / Sales 17.11% 33.36% 49.99% 54.23%
Announcement Date 22-04-18 22-04-18 23-04-23 24-04-21
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CHENGDA PHARMACEUTICALS CO., LTD. Stock ChengDa Pharmaceuticals Co., Ltd.
-10.81% 462M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.40% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.46% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.50% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.34% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+8.62% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301201 Stock
  4. Financials ChengDa Pharmaceuticals Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW